31528615 2022-01-01 2022-12-31 31528615 2022-01-01 2022-12-31 1 31528615 2022-01-01 2022-12-31 2 31528615 2022-01-01 2022-12-31 3 31528615 2022-01-01 2022-12-31 1 31528615 2022-01-01 2022-12-31 1 31528615 2021-01-01 2021-12-31 31528615 2020-01-01 2020-12-31 31528615 2019-01-01 2019-12-31 31528615 2018-01-01 2018-12-31 31528615 2022-12-31 31528615 2021-12-31 31528615 2020-12-31 31528615 2019-12-31 31528615 2018-12-31 31528615 2020-12-31 fsa:ContributedCapitalMember 31528615 2020-12-31 fsa:RetainedEarningsMember 31528615 2021-01-01 2021-12-31 fsa:ContributedCapitalMember 31528615 2021-01-01 2021-12-31 fsa:RetainedEarningsMember 31528615 2021-12-31 fsa:ContributedCapitalMember 31528615 2021-12-31 fsa:RetainedEarningsMember 31528615 2022-01-01 2022-12-31 fsa:ContributedCapitalMember 31528615 2022-01-01 2022-12-31 fsa:RetainedEarningsMember 31528615 2022-12-31 fsa:ContributedCapitalMember 31528615 2022-12-31 fsa:RetainedEarningsMember iso4217:DKK xbrli:pure Fredrik Björnulfson Abbott Laboratories A/S Emdrupvej 28C DK 2100 Copenhagen Ø 31528615 Copenhagen Bradley Jay Slater Chairman Fredrik Björnulfson Andreas Almroth Andreas Almroth Chief Executive Officer EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36 DK 2000 Frederiksberg The Board of Directors and the Executive Board have today considered and approved the annual report of Abbott Laboratories A/S for the financial year 01.01.2022 - 31.12.2022. The annual report has been prepared in accordance with the Danish Financial Statements Act. It is our opinion that the financial statements give a true and fair view of the Company's financial position at 31.12.2022 and of the results of the Company's operations for the financial year 01.01.2022 - 31.12.2022. Further, in our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's operations and financial position. We recommend that the annual report be approved at the annual general meeting. Copenhagen To the owners of Abbott Laboratories A/S We have audited the financial statements of Abbott Laboratories A/S for the financial year 1 January – 31 December 2022, which comprise income statement, balance sheet, statement of changes in equity, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January – 31 December 2022 in accordance with the Danish Financial Statements Act. We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Independence We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements and the IESBA Code. Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements. As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also: • Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. • Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. • Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management • Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern. • Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. Management is responsible for the Management's review. Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review. Copenhagen 30700228 Birgit Morville Schrøder State Authorised Public Accountant mne21337 268116000 259193000 195944000 162924000 128992000 51183000 44159000 39746000 39777000 22502000 8043000 7694000 6153000 7834000 2983000 -61000 -16000 136000 -32000 -2000 6098000 5974000 4825000 6040000 -2128000 207593000 183202000 164580000 178470000 187175000 11983000 3075000 6168000 11492000 913000 123788000 117689000 111715000 106890000 150850000 0.191 0.17 0.203 0.244 0.174 0.023 0.023 0.025 0.037 -0.016 0.051 0.052 0.044 0.047 -0.02 5.96 0.642 0.679 0.599 0.806 Primary activitiesThe Company’s activities consist of marketing, sale and distribution of, hospital supplies, electronic medical equipment and diagnostics equipment to the hospital and health sector in Denmark, the Faroe Islands and Iceland. Development in activities and finances Revenue for the year amounts to 268.116 thousand compared to 259.193 from last year. Profit after tax amounts to DKK 6.098 thousand versus DKK 5.974 thousand last year. Increased sales are mainly due to increased sales of FreeStyle Libre and delivery of Core Lab project. With sales that are increased from last year and higher than the expected outlook of DKK 230 - 240 mio., and the profit slightly lower than the expected of DKK 6 – 9 mio, Management considers the performance of the financial year satisfactory. Uncertainty relating to recognition and measurement Management evaluates that no particular uncertainties are related to recognition and measurement in connection with the presentation of the annual report. Outlook The company expects increasing revenue compared to 2022. For 2023 it is expected that the revenue will be from DKK 325 – 335 mio and the results will be from DKK 9 - 10 mio. New successful tenders, extension of current customer contracts and overall growth of market share due to the increase in the number of patients, support the maintenance and development of a high market share and thus contribute to the growth of net sales. Reporting class This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enter-prises (medium). The accounting policies used in the preparation of the financial statements are otherwise consistent with those of last year. Foreign currency translation On initial recognition, foreign currency transac tions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the one in effect at the payment date, or the rate at the balance sheet date, are recognised in the income statement as financial income or financial expenses. Property, plant and equipment, intangible assets, inventories and other non-monetary assets that have been purchased in foreign currencies are translated using historical rates. Operating leases The Company has chosen IAS 17 as interpretation for classification and recognition of leases. Lease payments on operating leases are recognised on a straight-line basis in the income statement over the term of the lease. Income statement Revenue The Company has chosen IAS 11/IAS 18 as interpretation for revenue recognition. Revenue from goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. On the conclusion of sales contracts that consist of several separate sales transactions, the contract price is split up into the individual sales transactions based on the relative fair value approach. The separate sales transactions are recognised as revenue when the criteria for sale of goods and services are met. A contract is split up into individual transactions when the fair value of each individual sales transaction can be estimated reliably and when each individual sales transaction represents a stand-alone value for the buyer. Sales transactions are deemed to have a stand-alone value for the buyer when the transaction is individually identifiable and usually sold separately. Revenue is measured at the fair value of the agreed consideration exclusive of VAT and taxes charged on behalf of third parties. All discounts and rebates granted are recognised in revenue. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed. Service agreements are accrued over the term of the agreements. Other operating income/expenses Other operating income/expenses comprises income of a secondary nature as viewed in relation to the Entity’s primary activities. Other operating income/expenses comprise of income from divestment of divisions. Costs of goods for resale and consumables Costs of goods for resale and consumables comprise the consumption of goods for resale and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary write-downs of the relevant inventories. Other external expenses Other external expenses include expenses relating to the Entity’s ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes write- downs of receivables recognised in current assets. Other external expenses also include research costs and costs of development projects that do not meet the criteria for recognition in the balance sheet. Staff costs Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc. for entity staff. Amortisation, depreciation and impairment losses Amortisation, depreciation and impairment losses relating to intangible assets and property, plant and equipment comprise amortisation, depreciation and impairment losses for the financial year, calculated on the basis of the residual values and useful lives of the individual assets and impairment testing as well as gains and losses from the sale of intangible assets as well as property, plant and equipment. Other financial income Other financial income comprises interest income, including interest income on receivables from group enterprises, net capital gains on payables and transactions in foreign currencies as well as tax relief under the Danish Tax Prepayment Scheme, etc. Other financial expenses Other financial expenses comprise interest expens es, including interest expenses on payables to group enterprises, net capital losses on payables and transactions in foreign currencies as well as tax surcharge under the Danish Tax Prepayment Scheme, etc. Income taxes Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity. The Company is jointly taxed with all Danish sister subsidiaries (Abbott Medical Danmark A/S & Abbott Rapid Diagnostics A/S). The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses). Balance sheet Property, plant and equipment Plant and machinery, other fixtures and fittings, tools and equipment as well as leasehold improvements are measured at cost less accumulated depreciation and impairment losses. Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be put into operation. The basis of depreciation is cost less estimated residual value after the end of useful life. Straight-line depreciation is made based on the following estimated useful lives of the assets: Plant and machinery 3-10 years Other fixtures and fittings, tools and equipment 3-10 years Leasehold improvements 3-10 years For leasehold improvements, assets subject to finance leases and for assets lent to customers recognised as operational lease contracts, the depreciation period cannot exceed the contract period. Property, plant and equipment are written down to the lower of recoverable amount and carrying amount. Investment in subsidiaries Investments in subsidiaries are measured at cost. Where cost exceeds the recoverable amount, write-down is made to this lower value. Dividends received are recognized in the income statement in the financial year in which they are declared. If proposed dividends exceed accumulated earnings after the acquisition date, dividends are however recognised as a reduction of the cost of the investment. The carrying amount of investments in subsidiaries is subject to an annual test for indications of impairment. Write-down is made to the recoverable amount if this is lower than the carrying amount. Impairment losses are recognized in the income statement. Deferred taxDeferred tax is recognised on all temporary differences between the carrying amount and tax-based value of assets and liabilities, for which the tax-based value of assets is calculated based on the planned use of each asset.Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at their estimated realisable value, either as a set-off against deferred tax liabilities or as net tax assets. Inventories Inventories are measured at the lower of cost using the FIFO method and net realisable value. Cost of goods for resale and consumables consists of purchase price plus delivery costs. The net realisable value of inventories is calculated as the estimated selling price less costs incurred to execute sale. Income tax payable or receivableCurrent tax payable or receivable is recognised in the balance sheet, stated as tax calculated on this year's taxable income, adjusted for prepaid tax. Receivables The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables. Receivables are measured at amortised cost, usually equalling nominal value less write-downs for bad and doubtful debts. Prepayments Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost. CashCash comprises cash in hand and bank deposits. Balances in the group's cash pool scheme are not, due to the nature of the scheme, considered cash, but are recognised under ‘Receivables from group entities'. Other provisions Other provisions comprise anticipated costs of non-recourse guarantee commitments and returns. Other provisions are recognised and measured as the best estimate of the expenses required to settle the liabilities at the balance sheet date. Warranty provisions comprise commitments to remedy defects and deficiencies within the guarantee period. Other financial liabilitiesOther financial liabilities are measured at amortised cost, which usually corresponds to nominal value. Prepayments received from customersPrepayments received from customers comprise amounts received from customers prior to delivery of the goods agreed or completion of the service agreed. Financial highlights Financial highlights are defined and calculated in accordance with "Recommendations & Ratios" issued by the Danish Society of Financial Analysts. Ratios Calculation formula Gross margin (%) Gross profit x 100 Revenue Net margin (%) Profit/loss for the year x 100 Revenue Return on equity (%) Profit/loss for the year x 100 Average equity Solvency ratio (%) Equity x 100 Total assets Ratios reflect Gross margin The Entity's operating gearing.Net marginThe Entity's operating profitability. Return on equity The Entity's return on capital invested in the Entity by the owners. Solvency ratio The financial strength of the Entity. Referring to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements are prepared. The financial statements for Abbott Laboratories A/S and its group entities are part of the consolidated financial statements for Abbott Laboratories. With reference to the section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The entity’s cash flow is part of the consolidated cash flow statement for the parent company, Abbott Laboratories, Abbott Park, Illinois, USA. 51182546 44159403 42144131 35256913 994935 1208556 8043480 7693934 367736 164240 428605 180301 7982611 7677873 1884251 1703559 6098360 5974314 259193466 178502320 36531743 268115994 175858662 41074786 4624064 4681240 375254 136967 34000 40000 5033318 4858207 97197666 97197666 97197666 97197666 102055873 102230984 15290802 5407090 15290802 5407090 51174682 69696404 2426997 261378 0 0 310066 293185 55248765 71557862 34822010 4180980 105361577 81145932 207592561 183201805 1337020 1306895 4026000 4026000 119761500 113663140 123787500 117689140 1766535 1865637 1766535 1865637 399928 2233240 5277481 4351825 61337541 42374104 14872802 14644755 150774 43104 82038526 63647028 82038526 63647028 207592561 183201805 4026000 107688826 111714826 0 5974314 5974314 4026000 113663140 117689140 0 6098360 6098360 4026000 119761500 123787500 2022 2021 2020 2019 2018 DKK DKK DKK DKK DKK Changes in contributed - capitalContributed capital beginning of year4.026.000 4.026.000 4.026.000 4.026.000 4.026.000 Contributed capital end of year 4.026.000 4.026.000 4.026.000 4.026.000 4.026.000 Number Par value Nominal value DKK DKK Contributed capital Ordinary shares 4.026 1.000 4.026.000 2022 2021 1. Staff costs DKK DKK Wages and salaries 38.589.965 32.160.222 Pension costs 3.165.963 2.771.509 Other social security costs 388.203 325.182 42.144.13135.256.913 44 39 Remuneration has not been paid to the Board of Directors in the financial year. Management remuneration is not disclosed in accordance with the exemption clause in section 98b of the Danish Financial Statements Act. 2022 2021 2. Amortisation, depreciation and impairment losses DKK DKK Depreciation on property, plant and equipment 994.935 1.208.556 994.9351.208.556 2022 2021 3. Other financial income DKK DKK Financial income from group enterprises 4.146 2.459 Other interest income 0 0 Currency translation adjustments 363.590 161.781 367.736164.240 4. Other financial expenses 2022 2021 DKK DKK Financial expenses to group enterprises 234.588 16.199 Other interest expenses 93.439 119.447 Currency translation adjustments 100.578 44.655 428.605180.301 2022 2021 5. Tax on profit/loss from ordinary activities DKK DKK Current tax 2.028.980 2.141.105 Change in deferred tax 107.760 (429.687) Adjustment relating to previous years (252.489) (7.859) 1.884.2511.703.559 Plant and Other Leasehold 6. Property, plant and equipment machinery fixtures and improve-fittings, tools mentsand equipment DKK DKK DKK Cost at 1 January 2022 7.249.781 367.104 60.000 Additions 11.658.343 324.525 0 Disposals (11.767.948) 0 0 Cost at 31 December 2022 7.140.176 691.629 60.000 Depreciation and impairment losses at 1 January (2.568.541) (230.137) (20.000) 2021 Depreciation for the year (902.698) (86.238) (6.000) Reversal regarding disposals 955.127 0 0 Depreciation and impairment losses at 31 (2.516.112) (316.375) (26.000) December 2022 Carrying amount at 31 December 2022 4.624.064 375.254 34.000 Plant and machinery mainly consist of equipment lent to customers recognized as operational lease contracts. 7. Investments Investment in subsidiaries DKK Cost at 1 January 2022 97.197.666 Cost at 31 December 2022 97.197.666 Revaluations at 1 January 2022 0 Revaluations at 31 December 2022 0 Carrying amount at 31 December 2022 97.197.666 Name and place Ownership Result Equity Subsidiary Abbott Medical Danmark A/S, Glostrup 100% 4.049.682 125.143.515 8. Trade Receivables 2022 2021 DKK DKK Trade receivables 51.174.682 69.696.404 Trade receivables with expiry over 12 months 10.450.430 13.063.038 9. Related parties Related parties with a controlling interest The following related parties have a controlling interest in Abbott Laboratories A/S: Name Registered office Basis of influence Abbott Laboratories Abbott Park, Illinois, USA Ultimate Parent St. Jude Medical International Luxembourg Parent Holding Transactions with related parties 2022 2021 Related party Country Revenue DKK DKK Abbott GmbH Germany Expense recharge 2.466.044 2.393.088 Sale of goods 185.181 266.793 Abbott Diagnostics Germany TP adjustment 20.914.319 0 Abbott Norge AS Norway Regional allocation 2.386.738 2.677.361 Sale of goods 479.957 0 Abbott Oy Finland Regional allocation 3.458.349 2.328.977 Expense recharge 100 0 Abbott Scandinavia AB Sweden Regional allocation 4.066.151 3.190.941Abbott Medical Denmark Danmark A/S Expense recharge 1.610.171 1.822.858 Total 35.567.010 12.680.018 2022 2021 Related party Country Cost DKK DKK Abbott Diagnostics GmbH Germany Product purchase 0 164.664.166 TP adjustment (5.673.644) 0 Abbott GmbHGermany Purchase of services 4.335.580 0 Product purchase 7.463.878 3.002.559 Expense recharge 0 10.212.692 Abbott GmbH, Germany Product purchase 229.983.956 0 Delkenheim Abbott Logistics BV Holland Expense recharge 59.610 0 Abbott International Ltd. USA Expense recharge 27.009 8.629 Abbott Laboratories Intl. USA Regional recharges 0 (215.658) Product purchase (391.267) 0 Abbott Laboratories Ltd UK Regional allocation 1.073.696 1.050.363Abbott Ireland, Sligo Ireland Expense recharge 52.387 20.004 Regional allocation 1.936.332 3.421.865 Abbott Norge AS Norway Regional allocation 4.558.355 4.167.452 Abbott Oy Finland Regional allocation 1.364.254 717.047 Abbott Scandinavia AB Sweden Regional allocation 5.996.697 5.455.006 Expense recharge 0 282.572 Abbott Italy Italy Product purchase 550.360 0 Abbott Rapid Diagnostic A/S (Alere A/S) Denmark Product purchase 0 18.249 Grand Total 251.337.203 192.804.946 Receivables from affiliated companies 2022 2021 Related party Country DKK DKK Abbott Medical Danmark A/S Denmark 1.610.170 0 Abbott GmbH Germany 168.580 261.378 Abbott Oy Finland 100 0 Abbott Norge AS Norway 479.957 0 Abbott Rapid Diagnostic A/S Denmark 168.190 0 Grand Total 2.426.997 261.378 Payables to affiliated companies 2022 2021 Related party Country DKK DKK Abbott Luxembourg Finance S.à r.l. Luxembourg 38.945.739 23.969.107 Abbott Diagnostics GmbH Germany 17.503.308 14.713.776 Abbott GmbH Germany 2.492.755 3.733.725 Abbott Ireland, Sligo Ireland 1.936.331 0 Abbott Italy Italy 226.442 (50.467) Abbott Laboratories Limited UK UK 239.768 0 Abbott Laboratories Intl. LLC USA (2.602) 0 Abbott Rapid Diagnostics A/S Denmark 0 18.249 Other sister companies (4.200) (10.286) Grand Total 61.337.541 42.374.104 10. Other provision 2022 2021 DKK DKK 1.865.637 Other provisions consist of provisions for non-recourse guarantee 1.766.535commitments 1.865.637 1.766.535The Company grants a warranty of 24 months on Diagnostics products and is obliged to repair or replace products which are not satisfactory. For our Free Style Libre products, the company grants a warranty of 3 and 12 months depending on the product. 11. Deferred tax 2022 2021 DKK DKK Deferred tax at 1 January (43.104) (472.791) Adjustment of the deferred tax for the year (107.670) 429.687 (150.774)(43.104) The deferred tax asset relates to:Property, plant and equipment (684.302)(542.188) Fixed asset investments 02 Inventories 159.73984.767 Receivables from sales and services 2.8294.222 Provisions 370.960410.093 (150.774)(43.104) 6098360 5974314 6098360 5974314 13. Unrecognised rental and lease commitments 2022 2021 DKK DKK Commitments under rental agreements or leases until expiry 4.224.741 3.987.804 Due within the next 12 months 2.902.593 2.318.537 14. Contingent liabilities 2022 2021 DKK DKK Guarantee and warranty commitments 0 5.109.094 Contingent liabilities 0 5.109.094 The Company participates in a Danish joint taxation arrangement with Danish sister subsidiaries, with Abbott Laboratories A/S as the management company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Company is therefore liable from the financial year 2013 for income taxes etc for the jointly taxed companies and from 01.07.2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed companies. 15. Ownership The Company is wholly owned by St. Jude Medical International Holding, 26, Boulevard Royal, L-2449 Luxembourg. 16. Consolidation Name and registered office of the Parent preparing consolidated financial statements: Abbott Laboratories, Abbott Park, Illinois, USA, https://www.abbottinvestor.com/financials/annual-reports 17. Events after the balance sheet date No events materially affecting the Company's financial position have occurred subsequent to the financial year-end. Annual report Auditor's report on audited financial statements ParsePort XBRL Converter 2022-01-01 2022-12-31 2021-01-01 2021-12-31 2023-06-12 Regnskabsklasse C, mellemstor virksomhed 1971-02-04 2023-06-12 31528615 Abbott Laboratories A/S Emdrupvej 28C 2100 Copenhagen Ø Opinion Basis for Opinion 2023-06-12